Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Portfolio Pulse from
Adaptimmune's lete-cel achieved the primary endpoint in a pivotal trial for synovial sarcoma and MRCLS, with 42% of patients showing clinical responses. The company plans a rolling BLA submission by the end of 2025.
November 13, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptimmune's lete-cel achieved a 42% response rate in a pivotal trial for synovial sarcoma and MRCLS, including six complete responses. The company plans a rolling BLA submission by the end of 2025.
The successful trial results for lete-cel, with a significant response rate, are likely to positively impact Adaptimmune's stock. The planned BLA submission indicates progress towards commercialization, which is a positive regulatory development.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100